Vasgene Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vasgene Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Vasgene Therapeutics: 3 sponsored US clinical trials, 3 recruiting.
Vasgene Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Urothelial Carcinoma, with 2 trials.
Upper-quartile sponsor footprint
Vasgene Therapeutics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Vasgene Therapeutics pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Metastatic Urothelial Carcinoma (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vasgene Therapeutics: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Vasgene Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Vasgene Therapeutics page
3 registered trials is a research-attention snapshot, not an endorsement of Vasgene Therapeutics or any single study.
- 3 of Vasgene Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Metastatic Urothelial Carcinoma is the condition Vasgene Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Urothelial Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vasgene Therapeutics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.